Celcuity To Participate in Upcoming Investor Conferences

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company based in Minneapolis, announced today that its CEO and Co-founder, Brian Sullivan, will represent the company at several upcoming investor conferences. These engagements include a fireside chat at the TD Cowen 46th Annual Healthcare Conference scheduled for March 4, 2026, at 10:30 a.m. ET, and a similar session at the Leerink Global Healthcare Conference on March 10, 2026, at 2:20 p.m. ET. Additionally, Celcuity will host one-on-one investor meetings at the Jefferies Biotech on the Beach Summit on March 11, 2026. Live webcasts for these events will be available on Celcuity's website, where a replay will subsequently be offered.

Celcuity focuses on developing targeted therapies for various solid tumor types, highlighting its lead candidate, gedatolisib. This drug is noted for its pan-PI3K and mTORC1/2 inhibition, which effectively blocks the PI3K/AKT/mTOR (PAM) pathway, a crucial mechanism in cancer progression. The company is currently engaged in significant clinical trials, including a Phase 3 trial called VIKTORIA-1 exploring gedatolisib in tandem with fulvestrant for HR+/HER2- advanced breast cancer, which has completed its patient enrollment. Furthermore, the company is also running another Phase 3 trial, VIKTORIA-2, to assess gedatolisib combined with other agents for the first-line treatment of the same cancer type, alongside a Phase 1/2 trial for prostate cancer.

For more details on Celcuity's clinical trials and upcoming presentations, stakeholders can visit the company's official website or follow its updates on social media platforms.

Celcuity Inc. (NASDAQ: CELC), a clinical-stage biotechnology company, has announced its participation in several upcoming investor conferences, presenting a unique opportunity for investors to engage directly with its leadership team. The company's CEO, Brian Sullivan, will be hosting fireside chats at the TD Cowen Healthcare Conference, the Leerink Global Healthcare Conference, and a one-on-one session during the Jefferies Biotech Summit.

Investors should view these conferences as opportunities to gain insights into the company's prospects, particularly regarding its lead therapeutic candidate, gedatolisib, an inhibitor targeting the PI3K/AKT/mTOR pathway. The completion of enrollment in the Phase 3 VIKTORIA-1 clinical trial and the ongoing VIKTORIA-2 study showcase Celcuity’s commitment to advancing its oncology pipeline. With recent clinical achievements, the market may respond positively to updates, potential partnerships, or trial outcomes discussed during these events.

The ongoing focus on HR+/HER2- advanced breast cancer and metastatic castration-resistant prostate cancer positions Celcuity favorably within the fast-evolving oncology landscape. Investors should monitor the outcomes of these trials closely, as positive results could significantly enhance the company's valuation and market position.

Participation in investor conferences also reflects transparency, a quality valued in the biotech sector. Investors are encouraged to take advantage of the live webcasts and replays available on the company’s website for thorough updates.

In conclusion, Celcuity represents an intriguing opportunity for those looking to invest in innovative oncology therapies. Keeping an eye on trial results and the insights shared during the conferences may prove beneficial for making informed investment decisions as the company navigates its clinical milestones.